triptorelin, Trelstar LA, for the palliative treatment of advanced prostate cancer
The FDA has approved the long-acting form of triptorelin, Trelstar LA, for the palliative treatment of advanced prostate cancer.
This specific topic you are searching for was not covered in the newsletter. In the process of putting together the newsletters, the editorial staff can only pick a limited number of topics. This forces us to cut topics that are still informative and useful. As an extra service to our subscribers we are offering the Detail-Document.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote